We examined 52 asymptomatic patients with IgM monoclonal gammopathy and correlated anti-myelin-associated glycoprotein (anti-MAG) IgM with the presence of subclinical neuropathy and, in 24 of these patients, with the development of symptomatic neuropathy during a follow-up interval of 40 to 144 months (mean, 75.3 months). Three of 6 patients (50%) with high (>1/6,400) anti-MAG IgM had subclinical neuropathy at entry compared with 2 of 46 patients (4.3%) with low or no reactivity. At follow-up, a symptomatic neuropathy occurred in 3 of 4 patients with high reactivity and in 3 of 21 patients with low or no reactivity. The correlation of high anti-MAG IgM with the presence of subclinical neuropathy or the development of symptomatic neuropathy supports its pathogenetic role in the neuropathy.
Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy / N. Meucci, L. Baldini, A. Cappellari, A. Di Troia, S. Allaria, G. Scarlato, E. Nobile-Orazio. - In: ANNALS OF NEUROLOGY. - ISSN 0364-5134. - 46:1(1999 Jul), pp. 119-22-122.
|Titolo:||Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy|
BALDINI, LUCA (Secondo)
SCARLATO, GUGLIELMO (Penultimo)
NOBILE-ORAZIO, EDUARDO (Ultimo)
|Parole Chiave:||Myelin-Associated Glycoprotein; Humans; Nervous System Diseases; Adult; Aged; Paraproteinemias; Middle Aged; Follow-Up Studies; Male; Female; Immunoglobulin M|
|Settore Scientifico Disciplinare:||Settore MED/26 - Neurologia|
Settore MED/15 - Malattie del Sangue
|Data di pubblicazione:||lug-1999|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1002/1531-8249(199907)46:1<119::AID-ANA18>3.0.CO;2-H|
|Appare nelle tipologie:||01 - Articolo su periodico|